Treatment for HBV-MN Patients in Chinese: An Open Parallel Controlled Trial

an Open Parallel Clinical Trial in HBV-GN Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01152060

Enrollment

Registered

2010-06-29

Start date

2010-01-31

Completion date

2010-11-30

Last updated

2010-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBVe-antigen, Proteinuria

Keywords

remission of proteinuria, HBVe-antigen

Brief summary

Lamivudine treatment for HBV-DNA negative HBV-GN patients.

Detailed description

lamivudine and predinisone treatment for HBV-DNA negative HBV-GN patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Adult HBV-GN patients with biopsy-proven MN, heavy protinuria, HBsAg or HBeAg positive, HBV-DNA negative

Exclusion criteria

* Primary MN patients, HBV-DNA positive

Outcome results